US Stock Market Move | BEIGENE (ONC.US) rose more than 3% with third-quarter revenue breaking 10 billion and raising its 2025 performance guidance.

On Thursday, BEIGENE (ONC.US) rose more than 3% to $332.26. According to the financial report, in the third quarter, BEIGENE's quarterly revenue surpassed 10 billion RMB, reaching 100.77 billion RMB, an increase of 41.1% year-on-year; product revenue continued to grow rapidly, reaching 99.54 billion RMB, an increase of 40.6% year-on-year. Thanks to the strong growth in the third quarter, BEIGENE raised its full-year performance guidance for 2025, expecting full-year revenue to be between 36.2 billion and 38.1 billion RMB, up from the previous range of 35.8 billion to 38.1 billion RMB. In the first three quarters of 2025, BEIGENE's revenue reached 27.595 billion RMB, an increase of 44.2% year-on-year, exceeding last year's full-year revenue of 27.21 billion RMB; the company's product revenue was 27.314 billion RMB, an increase of 43.9% year-on-year; net profit attributable to shareholders reached 1.139 billion RMB, mainly due to the substantial growth in product revenue and expense management, significantly improving operational efficiency. It is reported that the adjustment in revenue growth is mainly due to the leading position of zebatinib in the US market and its continued expansion in Europe and other important global markets. In addition, research and development expenses, sales and administrative expenses are expected to narrow to between 29.5 billion and 30.9 billion RMB, mainly benefiting from continued prudent investment to promote revenue and pipeline growth, achieving significant operational efficiency.